CPIX
Cumberland Pharmaceuticals Inc
8.00$
+0.9%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 74.2% | 73.0% | 70.2% | 73.7% | 66.4% | 48.0% | 51.8% | 54.1% | 49.4% | 43.7% | 48.2% | 48.2% | |
| 41.8% | 41.6% | 36.9% | 48.7% | 24.8% | 27.0% | 25.7% | 32.0% | 21.3% | 22.4% | 23.8% | 14.9% | |
| 57.3% | 57.4% | 53.7% | 53.7% | 32.1% | 27.0% | 25.7% | 32.0% | 21.3% | 22.4% | 23.8% | 14.9% | |
| 5.8% | 6.6% | 7.8% | 9.0% | 7.0% | 7.5% | 12.8% | 8.1% | 14.2% | 11.9% | 15.5% | 22.1% | |
| 5.9% | 4.6% | 5.8% | 7.2% | 24.7% | 8.5% | 11.0% | 10.0% | 10.6% | 5.6% | 5.3% | 8.1% | |
| 0.7% | 0.6% | 0.5% | 0.6% | 0.7% | 15.6% | 12.7% | 1.7% | 5.9% | – | – | – | |
| 0.0% | 0.0% | 0.0% | 0.0% | 0.7% | 0.8% | 0.9% | 1.0% | 1.0% | 1.1% | 1.2% | 1.2% | |
| 22.6% | 23.0% | 23.7% | 23.0% | 29.9% | 29.6% | 29.1% | 28.4% | 32.9% | 27.6% | 23.8% | 18.3% | |
| 15.4% | 16.4% | 21.7% | 31.4% | 50.7% | 51.1% | 51.4% | 49.6% | 61.3% | 64.2% | 70.2% | 68.1% | |
| 14.4% | 13.5% | 15.8% | 19.0% | 24.7% | 23.1% | 26.6% | 22.8% | 30.8% | 34.2% | 41.8% | 47.8% | |
| – | 1.8% | 4.4% | 10.5% | – | 0.9% | 3.3% | 1.1% | 0.2% | 0.4% | 7.2% | 0.6% | |
| 3.4% | 3.1% | 8.6% | 9.6% | 9.8% | 9.6% | 13.9% | 11.4% | 11.6% | 17.2% | 18.4% | 24.2% | |
| 0.0% | 1.8% | 4.4% | 10.5% | 17.7% | 17.7% | 15.5% | 17.8% | 17.4% | 15.6% | 13.5% | 6.8% | |
| 84.7% | 83.6% | 78.3% | 68.6% | 49.6% | 48.9% | 48.7% | 50.7% | 39.0% | 36.2% | 30.2% | 32.4% | |
| 19.7% | 21.3% | 19.9% | 12.6% | 4.2% | 1.2% | -2.2% | -6.7% | -12.1% | -21.4% | -31.7% | -34.9% | |
| 18.8% | 18.6% | 17.4% | 17.1% | 13.9% | 14.7% | 15.7% | 17.6% | 15.7% | 17.5% | 18.6% | 19.5% |
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.